vs
Amphastar Pharmaceuticals, Inc.（AMPH）とエナーパックツールグループ（EPAC）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $144.2M、エナーパックツールグループの約1.3倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 13.3%、差は0.1%）。エナーパックツールグループの前年同期比売上増加率が高い（-0.7% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $13.3M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs 2.1%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
エナーパックツールグループ社は旧Actuant社として1910年に設立され、本社をウィスコンシン州メノモニーフォールズに置く。長い歴史を持つ産業用工具企業であり、普通株式はニューヨーク証券取引所に上場され、ティッカーシンボルはEPACである。
AMPH vs EPAC — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $144.2M |
| 純利益 | $24.4M | $19.1M |
| 粗利率 | 46.8% | 50.7% |
| 営業利益率 | 19.4% | 19.8% |
| 純利益率 | 13.3% | 13.3% |
| 売上前年比 | -1.8% | -0.7% |
| 純利益前年比 | -35.7% | -11.9% |
| EPS（希薄化後） | $0.51 | $0.36 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $144.2M | ||
| Q3 25 | $191.8M | $167.5M | ||
| Q2 25 | $174.4M | $158.7M | ||
| Q1 25 | $170.5M | $145.5M | ||
| Q4 24 | $186.5M | $145.2M | ||
| Q3 24 | $191.2M | $158.7M | ||
| Q2 24 | $182.4M | $150.4M | ||
| Q1 24 | $171.8M | $138.4M |
| Q4 25 | $24.4M | $19.1M | ||
| Q3 25 | $17.4M | $28.1M | ||
| Q2 25 | $31.0M | $22.0M | ||
| Q1 25 | $25.3M | $20.9M | ||
| Q4 24 | $38.0M | $21.7M | ||
| Q3 24 | $40.4M | $24.4M | ||
| Q2 24 | $37.9M | $25.8M | ||
| Q1 24 | $43.2M | $17.8M |
| Q4 25 | 46.8% | 50.7% | ||
| Q3 25 | 51.4% | 50.1% | ||
| Q2 25 | 49.6% | 50.4% | ||
| Q1 25 | 50.0% | 50.5% | ||
| Q4 24 | 46.5% | 51.4% | ||
| Q3 24 | 53.3% | 48.8% | ||
| Q2 24 | 52.2% | 51.8% | ||
| Q1 24 | 52.4% | 51.6% |
| Q4 25 | 19.4% | 19.8% | ||
| Q3 25 | 13.2% | 23.8% | ||
| Q2 25 | 24.2% | 20.0% | ||
| Q1 25 | 21.9% | 21.2% | ||
| Q4 24 | 24.2% | 21.4% | ||
| Q3 24 | 29.8% | 18.9% | ||
| Q2 24 | 30.3% | 22.2% | ||
| Q1 24 | 27.9% | 21.3% |
| Q4 25 | 13.3% | 13.3% | ||
| Q3 25 | 9.0% | 16.8% | ||
| Q2 25 | 17.8% | 13.9% | ||
| Q1 25 | 14.8% | 14.4% | ||
| Q4 24 | 20.4% | 15.0% | ||
| Q3 24 | 21.1% | 15.4% | ||
| Q2 24 | 20.8% | 17.1% | ||
| Q1 24 | 25.1% | 12.9% |
| Q4 25 | $0.51 | $0.36 | ||
| Q3 25 | $0.37 | $0.51 | ||
| Q2 25 | $0.64 | $0.41 | ||
| Q1 25 | $0.51 | $0.38 | ||
| Q4 24 | $0.74 | $0.40 | ||
| Q3 24 | $0.78 | $0.44 | ||
| Q2 24 | $0.73 | $0.47 | ||
| Q1 24 | $0.81 | $0.33 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $139.0M |
| 総負債低いほど良い | $608.7M | $188.8M |
| 株主資本純資産 | $788.8M | $431.1M |
| 総資産 | $1.6B | $818.1M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.44× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $139.0M | ||
| Q3 25 | $276.2M | $151.6M | ||
| Q2 25 | $231.8M | $140.5M | ||
| Q1 25 | $236.9M | $119.5M | ||
| Q4 24 | $221.6M | $130.7M | ||
| Q3 24 | $250.5M | $167.1M | ||
| Q2 24 | $217.8M | $132.4M | ||
| Q1 24 | $289.6M | $153.7M |
| Q4 25 | $608.7M | $188.8M | ||
| Q3 25 | $608.6M | $190.0M | ||
| Q2 25 | $607.7M | $191.3M | ||
| Q1 25 | $603.9M | $192.5M | ||
| Q4 24 | $601.6M | $193.8M | ||
| Q3 24 | $596.4M | $195.0M | ||
| Q2 24 | $586.9M | $196.3M | ||
| Q1 24 | $594.0M | $245.5M |
| Q4 25 | $788.8M | $431.1M | ||
| Q3 25 | $776.7M | $433.7M | ||
| Q2 25 | $757.5M | $438.2M | ||
| Q1 25 | $751.3M | $406.0M | ||
| Q4 24 | $732.3M | $398.0M | ||
| Q3 24 | $727.7M | $392.0M | ||
| Q2 24 | $713.3M | $365.8M | ||
| Q1 24 | $672.4M | $336.9M |
| Q4 25 | $1.6B | $818.1M | ||
| Q3 25 | $1.7B | $827.9M | ||
| Q2 25 | $1.6B | $828.1M | ||
| Q1 25 | $1.6B | $776.6M | ||
| Q4 24 | $1.6B | $775.4M | ||
| Q3 24 | $1.5B | $777.3M | ||
| Q2 24 | $1.5B | $749.5M | ||
| Q1 24 | $1.6B | $769.3M |
| Q4 25 | 0.77× | 0.44× | ||
| Q3 25 | 0.78× | 0.44× | ||
| Q2 25 | 0.80× | 0.44× | ||
| Q1 25 | 0.80× | 0.47× | ||
| Q4 24 | 0.82× | 0.49× | ||
| Q3 24 | 0.82× | 0.50× | ||
| Q2 24 | 0.82× | 0.54× | ||
| Q1 24 | 0.88× | 0.73× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $16.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $13.3M |
| FCFマージンFCF / 売上 | 13.4% | 9.2% |
| 設備投資強度設備投資 / 売上 | 4.5% | 1.9% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 0.84× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $102.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $16.0M | ||
| Q3 25 | $52.6M | $55.3M | ||
| Q2 25 | $35.6M | $39.9M | ||
| Q1 25 | $35.1M | $7.5M | ||
| Q4 24 | $29.0M | $8.6M | ||
| Q3 24 | $60.0M | $44.4M | ||
| Q2 24 | $69.1M | $30.3M | ||
| Q1 24 | $55.3M | $13.3M |
| Q4 25 | $24.6M | $13.3M | ||
| Q3 25 | $47.2M | $52.3M | ||
| Q2 25 | $25.0M | $35.1M | ||
| Q1 25 | $24.4M | $1.8M | ||
| Q4 24 | $16.6M | $2.8M | ||
| Q3 24 | $46.2M | $37.9M | ||
| Q2 24 | $63.1M | $28.5M | ||
| Q1 24 | $46.5M | $11.7M |
| Q4 25 | 13.4% | 9.2% | ||
| Q3 25 | 24.6% | 31.2% | ||
| Q2 25 | 14.3% | 22.1% | ||
| Q1 25 | 14.3% | 1.2% | ||
| Q4 24 | 8.9% | 1.9% | ||
| Q3 24 | 24.1% | 23.9% | ||
| Q2 24 | 34.6% | 18.9% | ||
| Q1 24 | 27.1% | 8.5% |
| Q4 25 | 4.5% | 1.9% | ||
| Q3 25 | 2.8% | 1.8% | ||
| Q2 25 | 6.1% | 3.1% | ||
| Q1 25 | 6.3% | 3.9% | ||
| Q4 24 | 6.7% | 4.0% | ||
| Q3 24 | 7.2% | 4.1% | ||
| Q2 24 | 3.3% | 1.2% | ||
| Q1 24 | 5.1% | 1.1% |
| Q4 25 | 1.35× | 0.84× | ||
| Q3 25 | 3.03× | 1.97× | ||
| Q2 25 | 1.15× | 1.81× | ||
| Q1 25 | 1.39× | 0.36× | ||
| Q4 24 | 0.76× | 0.40× | ||
| Q3 24 | 1.48× | 1.82× | ||
| Q2 24 | 1.82× | 1.18× | ||
| Q1 24 | 1.28× | 0.75× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
EPAC
| Transferred At Point In Time | $126.0M | 87% |
| Other | $12.1M | 8% |
| Other Operating Segment | $6.1M | 4% |
